The role of hormone replacement therapy and the risk of development of ovarian cancer

Journal Title: Współczesna Onkologia - Year 2006, Vol 10, Issue 1

Abstract

Hormone replacement therapy (HRT), which is mainly used to relieve climacteric symptoms, increases a woman’s risk for breast cancer, uterine endometrial cancer, but the association with ovarian cancer is less clear. Based upon epidemiological research there is evidence that steroids hormones, primarily estrogens and progesterone have an impact on ovarian carcinogenesis. The latest data have indicated that estrogens favour neoplastic transformation within the ovarian surface epithelium. There has been demonstrated a differential expression of ER alpha or beta during ovarian carcinogenesis, with an overexpression of ER alpha as compared with ER beta in cancer. The loss of ER-beta expression may be an important event leading to the development of ovarian cancer. ER- beta is a regulator of proliferation and motility of ovarian cancer cells. On the other hand, high progesterone levels offer a protection against development of ovarian carcinoma and overexpression progesterone receptors, which in turn, is associated with favourable prognosis in patients with ovarian cancer. Recent prospective epidemiological studies have indicated that hormone replacement therapy in post menopausal women may increase ovarian cancer incidence and mortality, especially in the group of women who have undergone HRT for more than 10 years. Physicians counselling women about HRT must consider the unique needs of each patient, and attempt to weigh the benefits and risks on an individual basis.

Authors and Affiliations

Lubomir Bodnar, Gabriel Wcisło, Agnieszka Gąsowska-Bodnar, Cezary Szczylik

Keywords

Related Articles

Effectiveness evaluation of hemibody irradiation as palliative treatment of patients with multiple painful bone dissemination

Effectiveness of hemibody irradiation (HBI) of 61 patients with multiple painful bone dissemination treated between 2001-2004 was evaluated. 21 patients had UHBI and 40 LHBI. Pain intensity on an 11-degree scale, pain fr...

Primary adenocarcinoma of the appendix: a case report

The aim of this work was to assess the dependence between concentration of histamine in serum and primary mammary gland cancer tissue and activity of histamine metabolism enzymes. The work concerned 95 women age 38-70, d...

Squamous cell carcinoma antigen (SCC) in diagnostics and monitoring treatment of patients with cervical cancer

Squamous cell carcinoma antigen (SCC) is the first marker of squamous cell carcinoma and a member of the serin proteinase inhibitor family. Increased concentration of SCC occurs in squamous cancers of the region of the h...

Wyniki badania wczesnego wykrywania czerniaka, przeprowadzonego u mieszkańców Poznania

Śmiertelność z powodu czerniaka w Polsce i na świecie systematycznie wzrasta. Głębokość naciekania skóry pozostaje najsilniejszym czynnikiem predykcyjnym przeżycia chorych, a badanie lekarskie skóry jest szansą na wykr...

Epidemiology of lung cancer in the period from 1993 to 2002 in Konin and Piła, cities with discrete industrial-geographic structure

Introduction: Bad prognosis and permanent increase in the number of cases makes lung cancer the biggest problem of contemporary oncology. Scientific investigations prove that cigarette smoking is responsible for 80% of a...

Download PDF file
  • EP ID EP123523
  • DOI -
  • Views 67
  • Downloads 0

How To Cite

Lubomir Bodnar, Gabriel Wcisło, Agnieszka Gąsowska-Bodnar, Cezary Szczylik (2006). The role of hormone replacement therapy and the risk of development of ovarian cancer. Współczesna Onkologia, 10(1), 28-33. https://europub.co.uk/articles/-A-123523